Jefferies: Bayer's key pharmaceutical products face competitive risks

Jefferies stated that the pharmaceutical division of this German group should see an annual sales growth rate of 2% between 2025 and 2030, compared to the industry average of 5%. The analysts added that after the failure of a trial for a type of cardiac arrhythmia known as atrial fibrillation, the potential market for asundexian has significantly shrunk, and a competing drug, milvexian, from a certain exchange, may have more advantages. Jefferies noted that as for Bayer's Kerendia, the current momentum is good, but as a certain exchange and Mineralys Therapeutics are developing a new class of drugs, competitive threats are emerging ahead.